Evidence map›Paper›PMID 33376573›Full record

ArticleThe World Allergy Organization journal2020

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.

Hilda J I De Jong, Jaco Voorham, Glenis K Scadding, Claus Bachert, Giorgio Walter Canonica, Peter Smith, Ulrich Wahn, Dermot Ryan, Jose A Castillo, Victoria A Carter and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Hilda J I De JongObservational and Pragmatic Research Institute, Singapore.
Jaco VoorhamObservational and Pragmatic Research Institute, Singapore.
Glenis K ScaddingRoyal National Throat, Nose and Ear Hospital, University College London School of Medicine, London, UK.
Claus BachertGhent University Hospital, Ghent, Belgium.
Giorgio Walter CanonicaPersonalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, SANI-Severe Asthma Network, Milan, Italy.
Peter SmithGriffith University, Southport, QLD, Australia.
Ulrich WahnCharité Medical University, Berlin, Germany.
Dermot RyanUsher Institute, University of Edinburgh, Edinburgh, UK.
Jose A CastilloHospital Universitari Quirón Dexeus, Barcelona, Spain.
Victoria A CarterOptimum Patient Care, Cambridge, UK.
Ruth B MurrayOptimum Patient Care, Cambridge, UK.
David B PriceObservational and Pragmatic Research Institute, Singapore.
Observational & Pragmatic Research Institute · SGCharité - Universitätsmedizin Berlin · DEGhent University Hospital · BEGriffith University · AUHospital Universitario Dexeus · ESHumanitas University · ITRoyal National Throat Nose and Ear Hospital · GBUniversity of Aberdeen · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMP-AzeFlu (Dymista®; spray of azelastine/fluticasone propionate) is the most effective allergic rhinitis (AR) treatment available. Its effect on asthma outcomes in patients with AR and asthma is unknown.

methodsThis pre-post historical cohort study, using the Optimum Patient Care Research Database, included patients aged ≥12 years, from UK general practice with active asthma (defined as a recorded diagnosis, with ≥1 prescription for reliever or controller inhaler) in the year before or at the initiation date. The primary study outcome was change in number of acute respiratory events (i.e. exacerbation or antibiotic course for a respiratory event) between baseline and outcome years. The effect size of MP-AzeFlu was quantified as the difference in % of patients that improved and worsened.

resultsOf the 1,188 patients with AR and asthma included, many had a record of irreversible obstruction (67%), and uncontrolled asthma (70.4%), despite high mean daily doses of reliever/controller therapy and acute oral corticosteroid use, in the year pre-MP-AzeFlu initiation. MP-AzeFlu initiation was associated with fewer acute respiratory events (effect size (e) = 5.8%, p = 0.0129) and a reduction in daily use of short-acting β

conclusionsThis study provides the first direct evidence of the beneficial effect of MP-AzeFlu on asthma outcomes in co-morbid patients in primary care in the United Kingdom.

trial registrationEUPAS30940. Registered August 13, 2019.

Indexed as

ADEPT, Anonymized data ethics & protocol transparencyAR, Allergic rhinitisATS, American Thoracic societyBEC, Blood eosinophil countControlCRS, Chronic rhinosinusitisERS, European respiratory societyExacerbationsFEV1, forced expiratory volume in 1 sFVC, Forced vital capacityGERD, Gastroesophageal reflux diseaseGINA, Global initiative for asthmaICS, Inhaled corticosteroidINS, Intranasal corticosteroidNP, Nasal polypsOAC, Overall asthma controlOAH, Oral anti-histamineOCS, Oral corticosteroidOPCRD, Optimum patient care research databaseOTC, Over the counterPEF, Peak expiratory flow rateRCT, Randomized controlled trialRDAC, Risk domain asthma controlRescue medicationSABA, Short-acting β2-agonistSMD, Standardised mean differenceUK, United Kingdom

Identifiers

PMID33376573
PMCPMC7753940
OpenAlexW3113642199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.